Opening the iTunes Store.If iTunes doesn’t open, click the iTunes icon in your Dock or on your Windows desktop.Progress Indicator
Opening the iBooks Store.If iBooks doesn't open, click the iBooks app in your Dock.Progress Indicator

iTunes is the world's easiest way to organize and add to your digital media collection.

We are unable to find iTunes on your computer. To download from the iTunes Store, get iTunes now.

Do you already have iTunes? Click I Have iTunes to open it now.

I Have iTunes Free Download
iTunes for Mac + PC

Cardiac Biomarkers in Renal Disease: The Fog is Slowly Lifting (Editorials)

Clinical Chemistry 2004, Dec, 50, 12

This book is available for download with iBooks on your Mac or iOS device, and with iTunes on your computer. Books can be read with iBooks on your Mac or iOS device.


It has long been known that among patients with end-stage renal disease (ESRD), cardiac disease is the single greatest cause of mortality, accounting for nearly one half of all deaths (1). Among community-based populations, renal insufficiency is an independent predictor of the risk of subsequent ischemic heart disease, conferring a risk equivalent to that of diabetes (2). Furthermore, the presence of even moderate renal impairment in a patient presenting with an acute coronary syndrome (ACS) is a strong short-term prognostic indicator, significantly increasing the 30-day risk of myocardial infarction, heart failure, and cardiac death (3). Thus, a strong and pervasive link clearly exists between kidney failure and cardiac disease. The common challenge to the nephrologist, cardiologist, and emergency physician therefore lies in successfully recognizing those patients within their scope of practice who are most at risk, thereby allowing targeted application of interventions designed to circumvent adverse outcomes. Accordingly, there is an exigent need for the clinical laboratory to identify and make available reliable assays for biomarkers that can predict adverse events across a range of clinical settings and among patients with various degrees of kidney dysfunction, as well as to elucidate the performance characteristics and limitations of each of these markers. A variety of individual biomarkers have previously been evaluated for this purpose, and several have been found to successfully predict outcome in patients with kidney disease. These include markers of myocardial necrosis, such as cardiac troponin T (cTnT) and I (cTnI) (4); markers of heart failure, such as B-type natriuretic peptide (BNP) and its associated inactive N-terminal fragment (NT-proBNP) (5); and the marker of systemic inflammation, high-sensitivity C-reactive protein (hsCRP) (6). However, fulfillment of the obvious potential of these biomarkers to have a positive impact on the care of renal failure patients has been elusive because of unresolved clinical concerns that have caused application of these markers in this critical patient subgroup to lag behind their otherwise rapid integration in a broad spectrum of practice settings. In fact, it is fair to say that the short history of cardiac biomarker use among renal failure patients to date has been mostly characterized by controversy among scientists and confusion among clinicians.

Cardiac Biomarkers in Renal Disease: The Fog is Slowly Lifting (Editorials)
View in iTunes
  • 2,99 €
  • Available on iPhone, iPad, iPod touch, and Mac.
  • Category: Chemistry
  • Published: 01 December 2004
  • Publisher: American Association for Clinical Chemistry, Inc.
  • Print Length: 9 Pages
  • Language: English
  • Requirements: To view this book, you must have an iOS device with iBooks 1.3.1 or later and iOS 4.3.3 or later, or a Mac with iBooks 1.0 or later and OS X 10.9 or later.

Customer Ratings

We have not received enough ratings to display an average for this book.